<prompt> Bictegravir was approved by FDA recently forCystic fibrosisTBHypeensionHIV  <response>: Bictegravir an Integrase Inhibitor is a component of the fixed-dose combination product bictegraviremtricitabinetenofovir alafenamide brand name: Biktarvy, which received marketing approval for the treatment of HIV infection by U.S. Food and Drug Administration in February 2018. 